Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP697318.RA3Sb3GZkjvpC0O8Nf4mgMWsLsJ1hi3ihdt6A9T1Up3Vo130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP697318.RA3Sb3GZkjvpC0O8Nf4mgMWsLsJ1hi3ihdt6A9T1Up3Vo130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP697318.RA3Sb3GZkjvpC0O8Nf4mgMWsLsJ1hi3ihdt6A9T1Up3Vo130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP697318.RA3Sb3GZkjvpC0O8Nf4mgMWsLsJ1hi3ihdt6A9T1Up3Vo130_provenance.
- befree-2016 importedOn "2016-02-19" NP697318.RA3Sb3GZkjvpC0O8Nf4mgMWsLsJ1hi3ihdt6A9T1Up3Vo130_provenance.
- NP697318.RA3Sb3GZkjvpC0O8Nf4mgMWsLsJ1hi3ihdt6A9T1Up3Vo130_assertion wasGeneratedBy ECO_0000203 NP697318.RA3Sb3GZkjvpC0O8Nf4mgMWsLsJ1hi3ihdt6A9T1Up3Vo130_provenance.
- NP697318.RA3Sb3GZkjvpC0O8Nf4mgMWsLsJ1hi3ihdt6A9T1Up3Vo130_assertion wasDerivedFrom befree-2016 NP697318.RA3Sb3GZkjvpC0O8Nf4mgMWsLsJ1hi3ihdt6A9T1Up3Vo130_provenance.
- NP697318.RA3Sb3GZkjvpC0O8Nf4mgMWsLsJ1hi3ihdt6A9T1Up3Vo130_assertion SIO_000772 18847555 NP697318.RA3Sb3GZkjvpC0O8Nf4mgMWsLsJ1hi3ihdt6A9T1Up3Vo130_provenance.
- NP697318.RA3Sb3GZkjvpC0O8Nf4mgMWsLsJ1hi3ihdt6A9T1Up3Vo130_assertion evidence source_evidence_literature NP697318.RA3Sb3GZkjvpC0O8Nf4mgMWsLsJ1hi3ihdt6A9T1Up3Vo130_provenance.
- NP697318.RA3Sb3GZkjvpC0O8Nf4mgMWsLsJ1hi3ihdt6A9T1Up3Vo130_assertion description "[Primary screening with Hybrid Capture((R)) 2 (HC2) generally detects more than 90% of all CIN2, CIN3 or cancer cases, and is 25% (95% CI): 15-36%) relatively more sensitive than cytology at a cut-off of abnormal squamous cells of undetermined significance (ASC-US) (or low-grade squamous intraepithelial lesions (LSIL) if ASC-US unavailable), but is 6% (95% CI: 4-7%) relatively less specific.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP697318.RA3Sb3GZkjvpC0O8Nf4mgMWsLsJ1hi3ihdt6A9T1Up3Vo130_provenance.